Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemopurifier plus Pembrolizumab in Head and Neck Squamous Cell Cancer
NCT04453046Terminated
- Sponsor
- Aethlon Medical, Inc.
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Open-label trial in head and neck squamous cell carcinoma (HNSCC), sponsored by Aethlon Medical, Inc. Primary endpoint: Safety as measured by adverse events up to 2 years. Started Oct 2020; status: terminated.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04453046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453046.